Dengue candidate vaccine shows promise in phase 3 trial
Phase 3 clinical trial results for the most advanced dengue vaccine in development, known as CYD-TDV and made by Sanofi Pasteur, showed it is more than 50% protective overall and nearly 90% effective against the most serious, hemorrhagic form of the disease, according to a new study published in The Lancet.